ClinicalTrials.Veeva

Menu

Maternal Voice and Quantitative EEG (qEEG)

University of New Mexico (UNM) logo

University of New Mexico (UNM)

Status

Terminated

Conditions

Development Delay
Prematurity
Premature Birth

Treatments

Behavioral: Placebo Recording
Behavioral: Recorded Maternal Voice

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

A short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (NICU) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative EEG (spectral power density) as a marker of development.

Full description

This will be a randomized placebo-controlled clinical trial. Infants consented to participate will be randomized into the intervention arm or non-intervention arm by sealed unmarked envelope.

All consented participants will have an initial EEG of 60-90 minutes duration, performed at 32 5/7 - 32 6/7 weeks (and after 72 hours of life).

Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), eligible subjects will proceed with randomized intervention or placebo for a 2-week (14 day) intervention period.

All infants will receive a 2nd EEG of 30-60 minutes duration, performed between 35 0/7 - 35 6/7 weeks corrected gestational age, following completion of either the intervention or non-intervention arm (with the goal of the 2nd EEG occurring within 48 hours of infants having completed the intervention vs. non-intervention arm).

EEG technician and all persons reviewing, pruning and analyzing data from the qEEG will be blinded to whether the infant was in the intervention or the non-intervention arm.

Enrollment

14 patients

Sex

All

Ages

28 to 33 weeks old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Infants born at 28 0/7 - 32 3/7 weeks gestation (to allow for infants born at 32 3/7 weeks to have initial EEG performed after 72 hours of life and prior to initiating intervention or non-intervention arm at 33 0/7 weeks gestation)
  • Mother available to provide voice recording, and have ability to converse and read in English (as the scripted content for the intervention will be provided in English)

Exclusion criteria

  • Infant with Critical Congenital Cardiac Disease
  • Infant with Chromosomal anomaly or Inborn Error of Metabolism
  • Infant with known Neurologic disorder/abnormality - including hypoxic-ischemic encephalopathy (HIE), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), seizure activity, anatomic abnormality
  • Infant receiving antiepileptic or sedation medications prior to EEG
  • Initial EEG abnormal with epileptiform activity or not consistent with corrected gestational age
  • Mother not available to provide voice recording in English
  • Unable to obtain consent from mother due to maternal health issues following delivery (such as mother requiring intubation or sedation following delivery
  • Mothers who are prisoners (as the study team would like to have continuing communication during the study period as needed)
  • Mothers who are <18 years of age will not be approached for consent
  • Any mother that is not able to consent due to having a legal representative will not be approached for consent
  • Any infant that is planned to be placed for adoption, is in foster care or is a ward of the state

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

14 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the non-intervention arm will be played a blank recording of approximately 60 minutes duration, once every 24 hours for a 2-week (14 day) period.
Treatment:
Behavioral: Placebo Recording
Recorded Voice Exposure
Experimental group
Description:
Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), infants randomized to the intervention arm will be played a recording of their mother's voice with approximately 60 minutes of scripted content, once per 24 hours for a 2-week (14 day) intervention period. (Mothers will be recorded reading a children's book and the recording will be looped to create the 60 minutes of content).
Treatment:
Behavioral: Recorded Maternal Voice

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems